Cipla launches rapid antigen test kits for quick detection of COVID-19

Cipla launches rapid antigen test kits

Drug major Cipla has made has announced its partnership with the Premier Medical Corporation Pvt Ltd for commercialisation of the rapid antigen test kits for COVID-19 in India.


It can detect the viral disease in less than half an hour. “In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Pvt Ltd,” Cipla said in a regulatory filing.

The company said it will commence supply of rapid point-of-care nasopharyngeal swab tests from this week. The test will be marketed under the brand name ‘CIPtest’.

Also read: Cipla launches “Covi-G” for COVID-19 rapid antibody detection


This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit, which is a test kit to detect antibodies against the virus that causes Covid-19.

“CIPtest is a reliable high-performing kit that has been validated and approved by ICMR. It is found to have specificity and sensitivity of 98.09% and up to 75% respectively. It is not only rapid with a quick turn-around time, but also enables easy interpretation of results without the need of any additional instrument. Cipla’s expansive distribution network will help in ensuring supply of kits across the country,” a statement released from company said.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top